Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Avadel Pharmaceuticals PLC
Operating Income
Avadel Pharmaceuticals PLC
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Operating Income
-$5m
|
CAGR 3-Years
63%
|
CAGR 5-Years
31%
|
CAGR 10-Years
19%
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
Operating Income
$312.8m
|
CAGR 3-Years
23%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-8%
|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Operating Income
$517.6m
|
CAGR 3-Years
68%
|
CAGR 5-Years
0%
|
CAGR 10-Years
0%
|
|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Operating Income
-$60.7m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-167%
|
CAGR 10-Years
N/A
|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Operating Income
-€3.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
5%
|
|
|
Ovoca Bio PLC
LSE:OVB
|
Operating Income
-€249k
|
CAGR 3-Years
65%
|
CAGR 5-Years
36%
|
CAGR 10-Years
18%
|
|
Avadel Pharmaceuticals PLC
Glance View
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 66 full-time employees. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.
See Also
What is Avadel Pharmaceuticals PLC's Operating Income?
Operating Income
-5m
USD
Based on the financial report for Sep 30, 2025, Avadel Pharmaceuticals PLC's Operating Income amounts to -5m USD.
What is Avadel Pharmaceuticals PLC's Operating Income growth rate?
Operating Income CAGR 10Y
19%
Over the last year, the Operating Income growth was 92%. The average annual Operating Income growth rates for Avadel Pharmaceuticals PLC have been 63% over the past three years , 31% over the past five years , and 19% over the past ten years .
